drugset
drugset / Trial / NCT07243171

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

NCT07243171 ↗

Phase 1/2 Recruiting 84 enrolled Hangzhou Sciwind Biosciences Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity

Timeline

Start
2025-11-18
Primary completion
2026-08-03
Completion
2026-11-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Ecnoglutide Protein / enzyme biologic — Oral

Indications

obesity disorder